KETOCONAZOLE AND FLUCONAZOLE INHIBITION OF THE METABOLISM OF CYCLOSPORINE-A BY HUMAN LIVER IN-VITRO

Citation
G. Omar et al., KETOCONAZOLE AND FLUCONAZOLE INHIBITION OF THE METABOLISM OF CYCLOSPORINE-A BY HUMAN LIVER IN-VITRO, Therapeutic drug monitoring, 19(4), 1997, pp. 436-445
Citations number
55
Categorie Soggetti
Pharmacology & Pharmacy","Public, Environmental & Occupation Heath",Toxicology,Biology
Journal title
ISSN journal
01634356
Volume
19
Issue
4
Year of publication
1997
Pages
436 - 445
Database
ISI
SICI code
0163-4356(1997)19:4<436:KAFIOT>2.0.ZU;2-L
Abstract
The effects of the important antifungal agents, ketoconazole (Ket) and fluconazole (Flu), on the microsomal metabolism of cyclosporin A (CsA ) by seven human livers was measured in vitro, A total of eight CsA me tabolites were identified by high-performance liquid chromatography, w ith metabolites AM9 and AM1 predominating. Ket was a stronger inhibito r than Flu for the formation of each of the 8 metabolites; the mean IC 50 for the inhibition of total CsA metabolism was 0.26 +/- 0.08 mu M a nd 85.7 +/- 23.9 mu M for Ket and Flu, respectively. Inhibition by Ket and Flu was noncompetitive, with Ki = 0.13 mu M and 25.1 mu M, respec tively. There was considerable interindividual variation in the sensit ivity of CsA metabolism to inhibition by Ket or Flu and the degree of inhibition was not uniform across the range of individual CsA metaboli tes. In six of the seven livers tested, Ket and Flu inhibited the aggr egate formation of secondary metabolites (AM19, AM49, AM4N9, and AM1c) more than the aggregate formation of primary metabolites (AM9, AM1, a nd AM4N) and inhibited the formation of AM9 more than AM1. Although th e degree of inhibition of total CsA metabolism by Flu correlated direc tly with the control (uninhibited) rate of total CsA metabolism (r = 0 .95), no similar correlation for inhibition by Ket was noted, nor was the magnitude of inhibition by Ket and Flu related. The results are di scussed in relation to the inhibition of CsA metabolism by Ket and Flu in patients in vivo and to the possibility of changes in the efficacy and toxicity of CsA as a result of alterations in its metabolite prof ile.